JP2025512391A5 - - Google Patents
Info
- Publication number
- JP2025512391A5 JP2025512391A5 JP2024560376A JP2024560376A JP2025512391A5 JP 2025512391 A5 JP2025512391 A5 JP 2025512391A5 JP 2024560376 A JP2024560376 A JP 2024560376A JP 2024560376 A JP2024560376 A JP 2024560376A JP 2025512391 A5 JP2025512391 A5 JP 2025512391A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding domain
- multispecific antibody
- multispecific
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263330769P | 2022-04-13 | 2022-04-13 | |
| US63/330,769 | 2022-04-13 | ||
| US202263379100P | 2022-10-11 | 2022-10-11 | |
| US63/379,100 | 2022-10-11 | ||
| US202263382592P | 2022-11-07 | 2022-11-07 | |
| US63/382,592 | 2022-11-07 | ||
| US202363478881P | 2023-01-06 | 2023-01-06 | |
| US63/478,881 | 2023-01-06 | ||
| US202363480478P | 2023-01-18 | 2023-01-18 | |
| US63/480,478 | 2023-01-18 | ||
| PCT/US2023/065741 WO2023201309A1 (en) | 2022-04-13 | 2023-04-13 | Antibodies that bind pd-l1, pd-l2 and/or cd28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512391A JP2025512391A (ja) | 2025-04-17 |
| JP2025512391A5 true JP2025512391A5 (enExample) | 2026-04-22 |
Family
ID=88330395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024560376A Pending JP2025512391A (ja) | 2022-04-13 | 2023-04-13 | Ｐｄ－ｌ１、ｐｄ－ｌ２及び／またはｃｄ２８と結合する抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230383012A1 (enExample) |
| EP (1) | EP4508085A1 (enExample) |
| JP (1) | JP2025512391A (enExample) |
| CN (1) | CN119365490A (enExample) |
| WO (1) | WO2023201309A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP4149632A1 (en) | 2020-05-14 | 2023-03-22 | Xencor, Inc. | Heterodimeric antibodies that bind msln and cd3 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| WO2025090973A2 (en) * | 2023-10-27 | 2025-05-01 | Xencor, Inc. | Anti-trop2 x anti-pdl1 x anti-cd28 antibodies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US459007A (en) | 1891-09-08 | Porte | ||
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| EP2138478B1 (en) | 2007-04-17 | 2019-07-24 | Kao Corporation | Process for producing hydrogenolysis products of polyhydric alcohols |
| EP2598530A2 (en) | 2010-07-29 | 2013-06-05 | Xencor, Inc. | Antibodies with modified isoelectric points |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| EP3587448B1 (en) | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| PL3122781T3 (pl) | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| US10647768B2 (en) | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| RU2019102008A (ru) | 2016-06-28 | 2020-07-28 | Ксенкор, Инк. | Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CA3094318A1 (en) * | 2018-03-30 | 2019-10-03 | Merus N.V. | Multivalent antibody |
| EP4097129A1 (en) * | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| CN113461824A (zh) * | 2020-03-31 | 2021-10-01 | 普米斯生物技术(珠海)有限公司 | 一种构建多特异性抗体的平台 |
| US11919958B2 (en) * | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| US20220135684A1 (en) * | 2020-10-14 | 2022-05-05 | Xencor, Inc. | Bispecific antibodies that bind pd-l1 and cd28 |
-
2023
- 2023-04-13 US US18/300,302 patent/US20230383012A1/en active Pending
- 2023-04-13 EP EP23722248.4A patent/EP4508085A1/en active Pending
- 2023-04-13 CN CN202380046738.9A patent/CN119365490A/zh active Pending
- 2023-04-13 WO PCT/US2023/065741 patent/WO2023201309A1/en not_active Ceased
- 2023-04-13 JP JP2024560376A patent/JP2025512391A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023164986A5 (enExample) | ||
| EP3853257A4 (en) | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof | |
| JP2023113641A5 (enExample) | ||
| CN110312736A (zh) | Pd-l1结合多肽或化合物 | |
| JP2017176174A5 (enExample) | ||
| JP2023113681A5 (enExample) | ||
| JP2024037765A5 (enExample) | ||
| IL314993A (en) | Anti-cd28 x anti-psma antibodies | |
| WO2018105865A8 (ko) | 을레핀 공중합체 합성용 촉매 조성물 및 올레핀 공중합체의 제조 방법 | |
| JP2019046670A5 (enExample) | ||
| JP2014509837A5 (enExample) | ||
| DK1716181T3 (da) | CDR-reparerede antistoffer | |
| EP3807348A4 (en) | CELLULOSIC GELS, FILMS AND COMPOSITE MATERIALS WITH THE GELS AND METHODS FOR THEIR PRODUCTION | |
| JP2023153863A5 (enExample) | ||
| JP2022538215A5 (enExample) | ||
| JP2020523704A5 (enExample) | ||
| JP2022505925A5 (enExample) | ||
| IL276709B2 (en) | Sensor unit | |
| JP2023103231A5 (enExample) | ||
| JP2022544380A5 (enExample) | ||
| IL310578A (en) | Cldn18.2-targeting antibody, bispecific antibody and use thereof | |
| JP2024507827A5 (enExample) | ||
| JP2024038101A5 (enExample) | ||
| JP2023166412A5 (enExample) | ||
| JP2023100679A5 (enExample) |